Literature DB >> 30555132

Burkholderia cepacia complex outbreaks among non-cystic fibrosis patients in the intensive care units: A review of adult and pediatric literature.

Mohammad Abdallah1, Hassan A Abdallah2, Ziad A Memish3.   

Abstract

Burkholderia cepacia complex (Bcc) is a Gram-negative bacterium commonly found in moist environments and soil. Bcc species are associated with many outbreaks in intensive care units (ICUs). In this review, we describe the sources of Bcc outbreaks among non-cystic fibrosis (CF) patients in various ICUs that include neonatal intensive care units, pediatric intensive care units and adult ICUs. Also we summarize the risk factors and outcome predictors of Bcc infection or colonization in non-CF critically ill patients. Finally, we describe the infection control measures that are used to manage and prevent the spread of Bcc outbreaks. PubMed was searched from 1 January 1994 and 31 December 2017. We found 30 outbreaks of Bcc among non-cystic fibrosis patients in ICUs; 17 outbreaks occurred in adult ICUs. The source was identified in 22 outbreaks. B. cepacia was the most common Bcc species causing outbreaks in ICUs; it was detected in 21 outbreaks. Indwelling central lines, presence of renal failure on hemodialysis, multiple bronchoscopic procedures, and recent abdominal surgery are independently associated with the development of B. cepacia bacteremia, while prolonged duration on a mechanical ventilator, a large number of nebulized albuterol therapies delivered, and prescription of beta-lactam, aztreonam, or macrolide-vancomycin antibiotics are risk factors for respiratory tract acquisition of B. cepacia. Disease severity and age were the main significant independent predictors of 14-day mortality in adult ventilated non-CF patients with Bcc acquisition. Bcc species have been linked to many outbreaks in non-CF patients in ICUs. Strict application of infection control standards is critical to limit the emergence and spread of Bcc in ICU settings.

Entities:  

Mesh:

Year:  2018        PMID: 30555132

Source DB:  PubMed          Journal:  Infez Med        ISSN: 1124-9390


  7 in total

1.  Osteoarticular melioidosis: a retrospective cohort study of a neglected disease.

Authors:  Nitin Gupta; Shyamasunder N Bhat; Suhas Reddysetti; Rajagopal Kadavigere; Vishwapriya M Godkhindi; Chiranjay Mukhopadhyay; Kavitha Saravu
Journal:  Infez Med       Date:  2021-12-10

2.  An intermittent outbreak of Burkholderia cepacia contaminating hematopoietic stem cells resulting in infusate-related blood stream infections.

Authors:  Anis Raddaoui; Farah Ben Tanfous; Yosra Chebbi; Aymen Mabrouk; Wafa Achour
Journal:  J Infect Prev       Date:  2022-02-08

Review 3.  Burkholderia cepacia Complex Bacteria: a Feared Contamination Risk in Water-Based Pharmaceutical Products.

Authors:  Mariana Tavares; Mariya Kozak; Alexandra Balola; Isabel Sá-Correia
Journal:  Clin Microbiol Rev       Date:  2020-04-15       Impact factor: 26.132

4.  First cases of Burkholderia cenocepacia IIIA neonatal sepsis in Central African Republic.

Authors:  Thierry Frank; Julita Gil-Cuesta; Jean Robert Mbecko; Hugues Sanke; Chantal Lakis; Anne Le Flèche-Matéos; Alain Berlioz-Arthaud
Journal:  Pan Afr Med J       Date:  2020-08-24

5.  Activity of Aerosolized Levofloxacin against Burkholderia cepacia in a Mouse Model of Chronic Lung Infection.

Authors:  Mojgan Sabet; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 6.  Ethnobotany and the Role of Plant Natural Products in Antibiotic Drug Discovery.

Authors:  Gina Porras; François Chassagne; James T Lyles; Lewis Marquez; Micah Dettweiler; Akram M Salam; Tharanga Samarakoon; Sarah Shabih; Darya Raschid Farrokhi; Cassandra L Quave
Journal:  Chem Rev       Date:  2020-11-09       Impact factor: 60.622

7.  Outer membrane vesicles produced by Burkholderia cepacia cultured with subinhibitory concentrations of ceftazidime enhance pro-inflammatory responses.

Authors:  Se Yeon Kim; Mi Hyun Kim; Joo Hee Son; Seung Il Kim; Sung Ho Yun; Kyeongmin Kim; Shukho Kim; Minsang Shin; Je Chul Lee
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.